Otsuka vs. Sun Pharma reshapes Australian patent term extension rules for pharmaceutical formulations. The Full Court limits PTE to active ingredients per se, leaving controlled‑release aripiprazole depot products outside the extension regime and impacting lifecycle strategies.
Seagen vs. Daiichi Sankyo marks a major setback for broad biologics genus claims as the Federal Circuit overturned Seagen’s $41.8M jury verdict, invalidating US10808039B2 for lack of written description and enablement under the post Amgen v. Sanofi standard.
The PCSK9 Patent dispute saw a landmark UPC ruling that reinstated Amgen’s antibody patent, clarified core principles on inventive step, sufficiency, and claim interpretation, and strengthened legal certainty for innovators developing advanced biologic therapies across the European pharmaceutical & biopharmaceutical landscape.
A visual breakdown of the BMW R 1300 GS, comparing the production bike to its patent design from matrix LED headlight to GS Flyline and chassis.
Apple patent for avatar technology introduces a real-time system that mirrors users’ facial movements to create natural, expressive digital avatars. By enhancing realism, reducing manual controls, and improving efficiency, this innovation transforms virtual communication across video conferencing, gaming, social media, and immersive digital environments.
Samsung’s latest patent application discloses a smart hinge system for Samsung Smart Glasses, designed to fit every head size comfortably. Using pulleys, wires, and springs, the glasses maintain constant pressure and angle, improving comfort, stability, and the overall AR experience.
In the case of Allergan vs. Sandoz, the United States Court of Appeals for the Federal Circuit (CAFC) has invalidated a key Allergan patent covering the use of prostaglandin F (PGF) analogs for hair growth, handing a significant win to generic manufacturer Sandoz Inc.
Recently, The High Court of Delhi delivered a judgment in FMC v. Natco, a case between FMC Corporation and others (“FMC group”) and Natco Pharma Limited (“Natco”).
In a landmark decision concerning SPC for Durvalumab, the District Court of The Hague upheld the Dutch Intellectual Property Office’s (IPO) refusal to grant a Supplementary Protection Certificate (SPC) for AstraZeneca’s cancer immunotherapy drug Durvalumab, marketed as Imfinzi®. Durvalumab is an anti-PD-L1 antibody used in treating various cancers, and the refusal of SPC status has … Read more
Meta Platforms, Inc., the parent company of Facebook, filed a petition with the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) on November 10, 2025, seeking to invalidate all claims of SitNet’s U.S. Patent No. 12,256,463 B2. Basic Details of the Petition: Basic information of the Patent (463)? The 463 patent claims … Read more
